Galderma UK would like to notify you of an error identified by Galderma regarding specific batches of Tetralysal 300mg Hard Capsules, sold and distributed in the UK. The error identified relates to approved safety-related variations to the PIL that were not implemented, resulting in an older version of artwork being used and packed within finished batches. Additional warnings, precautions and side effects have been updated in the latest version of the PIL.
Further information and advice for healthcare professionals can be found on the MHRA website.
Want the latest pharmacy news and updates straight to your inbox?
Sign up to our regular newsletter for the latest guidance, news, events and CPD opportunities.
Sign Up
Become an RPS Member today and save up to £26 by choosing annual Direct DebitOR spread the cost by switching to monthly payments.
RPS membership is better value than ever in 2024 - join today!
BECOME A MEMBER TODAY